JP4980220B2 - Ｋｕｎｉｔｚ型組換え阻害因子 - Google Patents

Ｋｕｎｉｔｚ型組換え阻害因子 Download PDF

Info

Publication number
JP4980220B2
JP4980220B2 JP2007531547A JP2007531547A JP4980220B2 JP 4980220 B2 JP4980220 B2 JP 4980220B2 JP 2007531547 A JP2007531547 A JP 2007531547A JP 2007531547 A JP2007531547 A JP 2007531547A JP 4980220 B2 JP4980220 B2 JP 4980220B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
tumor
composition according
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007531547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512992A (ja
JP2008512992A5 (enExample
Inventor
シユジンスキー−タバツシイ，アナ・マリーザ
マリア，ドウルバネイ・アウグスト
バチスタ，イザベル・デ・フアチマ・コレイア
オー，パウロ・リー
Original Assignee
ウニアン・キミカ・フアルマセウチカ・ナシオナル・エシ／アー
フンダサオ・デ・アムパロ・ア・ペスキーサ・ド・エスタド・デ・サン・パウロ−エフイ・ア・ペー・エ・エシ・ペー
シユジンスキー−タバツシイ，アナ・マリーザ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニアン・キミカ・フアルマセウチカ・ナシオナル・エシ／アー, フンダサオ・デ・アムパロ・ア・ペスキーサ・ド・エスタド・デ・サン・パウロ−エフイ・ア・ペー・エ・エシ・ペー, シユジンスキー−タバツシイ，アナ・マリーザ filed Critical ウニアン・キミカ・フアルマセウチカ・ナシオナル・エシ／アー
Publication of JP2008512992A publication Critical patent/JP2008512992A/ja
Publication of JP2008512992A5 publication Critical patent/JP2008512992A5/ja
Application granted granted Critical
Publication of JP4980220B2 publication Critical patent/JP4980220B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2007531547A 2004-09-15 2005-09-15 Ｋｕｎｉｔｚ型組換え阻害因子 Expired - Lifetime JP4980220B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
BRPI0406057-1 2004-09-15
PCT/BR2005/000185 WO2006029492A1 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.

Publications (3)

Publication Number Publication Date
JP2008512992A JP2008512992A (ja) 2008-05-01
JP2008512992A5 JP2008512992A5 (enExample) 2008-10-30
JP4980220B2 true JP4980220B2 (ja) 2012-07-18

Family

ID=36273230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531547A Expired - Lifetime JP4980220B2 (ja) 2004-09-15 2005-09-15 Ｋｕｎｉｔｚ型組換え阻害因子

Country Status (10)

Country Link
US (1) US8440795B2 (enExample)
EP (1) EP1799707B1 (enExample)
JP (1) JP4980220B2 (enExample)
CN (1) CN101142232B (enExample)
AU (1) AU2005284615B2 (enExample)
BR (1) BRPI0406057B1 (enExample)
CA (2) CA2581001C (enExample)
DK (1) DK1799707T3 (enExample)
ES (1) ES2410160T3 (enExample)
WO (1) WO2006029492A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109976A1 (en) * 2007-03-14 2008-09-18 União Química Farmacêutica Nacional S/A Kunitz-type recombinant inhibitor
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
NZ593815A (en) 2008-12-19 2013-05-31 Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
BR102018074043A2 (pt) * 2018-11-22 2020-06-02 Inst Butantan composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias
BR102018074037A2 (pt) * 2018-11-22 2021-05-11 Inst Butantan composto para direcionar entidades moleculares para o domínio intracelular de células neoplásicas, ingrediente farmacêutico ativo compreendendo o referido composto, composição farmacêutica, método para o diagnóstico, prognóstico e/ou tratamento de câncer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006207C2 (de) * 1980-02-15 1982-10-21 Siemens AG, 1000 Berlin und 8000 München Elektrische Maschine mit einem Ständerblechpaket aus kornorientierten Blechen
DE3819078A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Also Published As

Publication number Publication date
BRPI0406057B1 (pt) 2021-10-26
CA2581001C (en) 2011-05-03
US20090042786A1 (en) 2009-02-12
ES2410160T3 (es) 2013-07-01
WO2006029492A1 (en) 2006-03-23
DK1799707T3 (da) 2013-05-21
CN101142232A (zh) 2008-03-12
BRPI0406057A (pt) 2006-05-02
JP2008512992A (ja) 2008-05-01
AU2005284615A1 (en) 2006-03-23
US8440795B2 (en) 2013-05-14
CA2680759A1 (en) 2008-09-18
AU2005284615B2 (en) 2011-03-31
EP1799707A1 (en) 2007-06-27
CA2581001A1 (en) 2006-03-23
EP1799707B1 (en) 2013-03-27
CN101142232B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
Jiang et al. Three pairs of protease-serpin complexes cooperatively regulate the insect innate immune responses
JP4163517B2 (ja) フォンビルブラント因子（ｖＷＦ）切断酵素
Moreau et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family
US6689582B1 (en) Polynucleotide molecules encoding proteins having proteinase inhibitor activity
JPH0584083A (ja) 新規ポリペプチド、それをコードする新規ｄｎａ、新規ポリペプチドの製造方法、新規医薬組成物、および新規酵素阻害方法
KR20030057545A (ko) 잠복형 안티트롬빈 ｉｉｉ의 제조방법
US8440795B2 (en) Kunitz-type recombinant inhibitor
KR100335536B1 (ko) 트롬빈억제제
EP2970434B1 (en) Dual reactivity potent kunitz inhibitor of fibrinolysis
KR101296367B1 (ko) 프로테아제 억제 단백질 및 그 이용
JP2011506489A (ja) 止血をモジュレートする組成物およびその使用法
WO2007101602A9 (en) Chimeric kunitz domains and their use
CN106432483A (zh) 沼水蛙皮肤丝氨酸蛋白酶抑制肽及其基因和制药应用
AU2008226358A1 (en) Kunitz-type recombinant inhibitor
CN100494366C (zh) 血凝酶
US8106002B2 (en) Anti-cancer agent comprising protein C inhibitor
CN106928334A (zh) 约安巨马陆抗血栓肽Joannsin及其应用
CN1298743C (zh) 一种融合蛋白及其编码基因与应用
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
WO2009030093A1 (fr) Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine
TW200846356A (en) Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
CN100389125C (zh) 无指盘臭蛙丙精肽、基因和变异体
CN102924606A (zh) 靶向肿瘤细胞抗肿瘤溶栓双效嵌合蛋白及其制备方法和应用
WO2009123573A1 (en) Anticoagulants derived from naja nigricollis snake venom
JPH07242700A (ja) 新規ポリペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120403

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120418

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150427

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4980220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250